The ChiNext Index, China’s NASDAQ-style board for high-growth startups, experienced a dramatic intraday reversal on Wednesday, April 15, 2026. After hitting its highest level since June 2015 in early trading, the index surrendered its gains to close down 1.22%. This pullback snapped a five-day winning streak, signaling a bout of profit-taking at a psychologically significant price ceiling that has haunted the exchange for over a decade.
Market activity remained exceptionally high, with combined turnover on the Shanghai and Shenzhen exchanges reaching 2.42 trillion yuan (approximately $334 billion). Despite the robust liquidity, the broader market sentiment skewed bearish as more than 3,500 individual stocks ended the day in the red. The high-volume decline suggests a major churn in capital as investors rotate out of overextended growth sectors into defensive or niche thematic plays.
Pharmaceutical stocks emerged as a rare bright spot, surging against the broader market trend. Several domestic pharmaceutical giants hit their daily upward limits, driven by a rotation into lower-valuation defensive assets. Meanwhile, niche technology themes such as computing power leasing and commercial aerospace maintained momentum, even as broader hardware and semiconductor sectors faced a sharp correction. The divergence highlights a fragmented market where liquidity is increasingly concentrated in a handful of speculative narratives.
On the downside, the lithium battery and energy storage sectors faced a collective slump, with some major suppliers falling as much as 12%. This correction in the green energy supply chain, coupled with a sell-off in memory chips and high-performance computing hardware, dragged down the tech-heavy benchmarks. The Shenzhen Component Index similarly fell by nearly 1%, reflecting a cautious outlook on the manufacturing and technology ecosystems that have driven recent gains.